|
|
Article: New Clinical Study Shows Children Prefer ACCOLATE Tablet Therapy to Commonly Used Inhaled Corticosteroid for Daily Treatment of Asthma.
- Article from:
- PR Newswire
- Article date:
- September 21, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
GENEVA, Switzerland, Sept. 21 /PRNewswire/ -- Data released today at the European Respiratory Society (ERS) annual meeting show that 70 percent of children with asthma (ages 12-17) prefer the tablet therapy ACCOLATE(R) (zafirlukast) from Zeneca Pharmaceuticals over treatment with the inhaled corticosteroid beclomethasone dipropionate (BDP).
ACCOLATE was the first medication from the first new class of asthma controller therapies -- called leukotriene receptor antagonists (LTRAs) -- to be introduced in nearly 25 years. In the United States, ACCOLATE is indicated for the preventive and chronic treatment of asthma in patients 12 years of age and older. The drug has ...